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for all-cause mortality was 1.54 (1.41, 1.67) with about 
one life-year lost over the study period. There was a trend 
to decreasing SMR (2% annually, p = .07). Mortality was 
higher compared with the general population for circula-
tory system diseases, respiratory system diseases, muscu-
loskeletal system diseases, and digestive system diseases 
(p < .05). The observed mortality among patients with RA 
was 54% higher than in the general population after adjust-
ment for age, sex and calendar year. More than one life-
year was lost over 15 years, and the mortality tended to 
decrease over time. The mortality was higher for cardiovas-
cular, respiratory, musculoskeletal and digestive diseases.
Keywords Rheumatoid arthritis · Mortality · Cause of 
death · Comorbidity · Cohort study · Longitudinal studies · 
Survival
Introduction
Patients with rheumatoid arthritis (RA) have a higher mor-
tality risk than the general population. Mortality rates in 
persons with RA are around 1.5 times higher than in the 
general population, with similar patterns over the last 
50 years [1].
Causes of death that are increased in comparison with 
the general population are cardiovascular diseases, respira-
tory diseases and infections. The higher mortality rate is 
particularly caused by cardiovascular (CV) disease [2–7], 
but only partly caused by the higher prevalence of cardio-
vascular risk factors [8, 9]. The additional risk depends 
on systemic inflammation [10]. Other increased causes of 
death are respiratory diseases and infections [6, 7, 11] most 
often due to respiratory infection/pneumonia [4–6]. The 
increased infection risk may be attributed to the impaired 
Abstract The aim of this study was to investigate (a) the 
mortality in a clinical cohort of patients with established 
rheumatoid arthritis in comparison with the general Dutch 
population over 15 years, (b) the trend in the mortality ratio 
during the study period, and (c) causes of death and com-
pare these with the general population. In 1997, a sample 
of 1222 patients was randomly selected from the register 
of a large rheumatology outpatient clinic. Their mortal-
ity and primary causes of death between 1997 and 2012 
were obtained from Statistics Netherlands. The standard-
ized mortality ratio (SMR) for all-cause mortality and the 
number of life-years lost in the study period, adjusted for 
age, sex, and calendar year, were calculated. A linear pois-
son regression analysis was performed to evaluate change 
in all-cause SMR over time. Finally, the SMRs for cause-
specific mortality were calculated. The mean age of the 
population at baseline was 60.4 (SD 15.4) years, and 72.6% 
of the patients were women. The estimated SMR (95% CI) 
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immune function in RA or an effect of immunosuppres-
sive therapy. In the most recent studies investigating cause-
specific mortality, only a limited number of causes of death 
were studied [12], the number of patients who died during 
follow-up was small, and most data came from studies con-
ducted before 2004 [11, 13]. There is thus a need to study 
the cause-specific mortality for a wide range of causes, in a 
large cohort, using more recent mortality data.
The treatment of patients with RA has been improved 
over time. The focus is now on tight disease control with 
much earlier initiation of intensive treatment [14]. From the 
1990s, high-dose treatment with disease-modifying anti-
rheumatic drugs (DMARDs), particularly methotrexate 
started and biologicals were applied from 2000 onwards. 
Meta-analyses suggest that DMARDs (particularly meth-
otrexate) reduce CV risk [15] and there is accumulating 
observational evidence that this also applies for biologicals, 
particularly the TNF blockers [16, 17].
Although the management of RA has improved, out-
comes about mortality rates of observational studies that 
started around 2000 differ. Some studies report that the 
mortality in patients with RA was similar to that of the 
general population [18, 19], while other studies showed 
that the mortality in patients with RA was higher [20, 21] 
or that the mortality gap with the general population was 
even increasing [11]. Reason for the different results can 
be the changing RA treatment during the last two decades 
as described above [14] or to the different types of cohorts 
and follow-up time [22]. Given these conflicting results, 
there is thus also an obvious need to evaluate the risk of 
mortality in a large sample of patients with RA, over a long 
period, using more recent mortality data. The need to study 
the mortality in long-term clinical cohorts of RA patients 
was underscored by a recent editorial [23].
Hence, the objectives of this study were (a) to investi-
gate the mortality in a clinical cohort of patients with estab-
lished RA and to compare this with the general Dutch pop-
ulation, (b) to assess the trend in the mortality ratio during 
the study period, and (c) to examine the causes of death.
Patients and methods
Study design and population
In 1997, our research group started a cohort study on 
comorbidity [24] and the impact on health outcomes and 
mortality [25–27] in patients with RA. A sample of 1222 
patients was randomly selected from the register of a 
large rheumatology outpatient clinic in Amsterdam, which 
included the patients from seven allied outpatient clin-
ics. For inclusion in the study, patients had to fulfil the 
following eligibility criteria: (a) be diagnosed with RA 
according to the American College of Rheumatology 
(ACR) Criteria for RA [28], (b) be 16 years of age or older, 
and (c) have visited a rheumatologist at least once in the 
previous 2 years.
Assessments
All 1222 patients were linked to Statistics Netherlands’ 
mortality records for the period 1997–2012 [29, 30]. The 
linkage of the patients to the mortality data was anony-
mous, using only date of birth, sex, and, if available, civil 
registration number, and was performed by staff of Sta-
tistics Netherlands [31]. Its databank provides death/life 
status, death dates, and primary and secondary causes of 
death. For this study, we used primary causes of death only. 
Causes of death were classified according to the Internal 
Classification of Diseases system (ICD-10) of the World 
Health Organization [32]. For patients who could not be 
linked to these records, data were obtained from the out-
patient clinic register. In order to compare patients with the 
general population, age and sex specific mortality data and 
causes of death for the general population were provided 
by Statistics Netherlands [30].
Statistical analyses
The standardized mortality ratio (SMR) was computed in 
order to compare the mortality in the RA cohort with the 
general population. The SMR was calculated as the ratio 
of the number of observed deaths in a study population 
divided by the number of expected deaths if the study pop-
ulation had the same age, sex, and calendar year specific 
rates as the general population. To calculate the expected 
death rates, we used the mortality rates of all Dutch inhabit-
ants. So, in calculating the expected number of deaths there 
was adjusted for age, sex, and calendar year. We calculated 
the SMR for all-cause mortality, for each year, the mean of 
3 years, the mean of 5 years, and the mean of all 15 years.
The number of life-years lost was calculated as follows. 
First, the partial life expectancy for the RA cohort was cal-
culated from the start of the study to 15 years later. This 
was also done for the general Dutch population, using a 
sex- and age-matched cohort. Second, we calculated the 
difference in the expected life-years during the study period 
between the RA cohort and the general population.
To investigate if there was a trend towards an increase or 
decrease in the SMR over time, a poisson regression analy-
sis was performed with log link function. Because there are 
only a few points in time, a simple model was used. Both 
identity link function and log link function showed a good 
fit when checking the deviance of the residuals [33].
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Because the exact date of inclusion in the cohort was 
not clear, and as this might bias the calculated SMR 
for this year, the 1997 data were excluded from this 
analysis.
Finally, the SMR for cause-specific mortality was calcu-
lated. Because of limited numbers, we calculated the mean 
SMR for all 15 years.
Results
Study population
Of the 1222 patients who were selected at baseline, 1208 
patients (99%) could be linked to Statistics Netherlands. 
Of the 14 patients who could not be linked, five died, 
according to the outpatient clinic’s register. For these 
five patients, no information about cause-specific mortal-
ity was available. No information about mortality could 
be obtained for nine patients. These nine patients were 
excluded from the analyses. Therefore, data of 1213 
patients were used for our analyses. The mean age of these 
patients at baseline was 60.4 (SD 15.4) years, and 72.6% 
of the patients were women. Data on disease duration were 
available for a sub-cohort of patients (n = 882). The mean 
disease duration in this sub-cohort was 5.0 (IQR 2.0–14.0) 
years [18]. A total number of 540 patients died during the 
study period. The relative number of patients that died dur-
ing the study period was 45% (540/1213). We expected 
based on the mortality rates of the general population that 
29% (352/1213) would have died during the study period 
(Table 1). 
All‑cause mortality
The estimated SMR (95% confidence interval) for all-cause 
mortality was 1.54 (1.41, 1.67) over the period of 15 years. 
This indicates a 54% higher risk of mortality compared 
with the general Dutch population. In females, it was 1.62 
(1.46, 1.80), and in males, it was 1.32 (1.13, 1.55).
The partial life expectancy for the Dutch population 
for the same period of 15 years was 13.4 years. The corre-
sponding life expectancy for the RA cohort was 12.2 years. 
The number of expected life-years the RA cohort lost com-
pared with the general population during the study period 
was 1.2 years.
Change in all‑cause mortality
Figure 1 shows the annual SMR. Table 2 shows the mean 
SMR for all-cause mortality over 3 years, over 5 years, and 
over the total study period. The outcome of the regression 
analysis showed that there was a trend to decreasing SMR 
(2% annually, p = .07). 
Cause‑specific mortality
The most frequent causes of death for the RA cohort were 
circulatory system diseases (32%), neoplasms (21%), and 
respiratory system diseases (12%). Table 3 shows the SMR 
for all causes of death compared with the general Dutch 
population. The RA cohort mortality was higher for circu-
latory system diseases, respiratory system diseases, muscu-
loskeletal system diseases, and digestive system diseases 
(p < .05).
Discussion
This 15-year study showed that the mortality in patients 
with RA is still higher than that of the general population, 
but seems to decrease over time. Mortality was higher for 
circulatory, respiratory, musculoskeletal, and digestive sys-
tem diseases.
Patients with RA had a 54% higher risk of mortality 
compared with the general population. This shows that 
excess mortality in RA still occurs and that the overall mor-
tality rate is still as high as it was in the past decades [1, 
34].
The number of life-years lost during the 15-year study 
period compared with the general population was about 
1 year. The mean age at baseline was 60 years, and the 
15 year follow-up period is, roughly, half the period needed 
to observe the full life expectancy. Under this assumption, 
this results in the estimated total number of life-years lost 
being of 2 years for a 60-year-old patient.
Table 1  Number of observed deaths for each year of the study period
Year N Total Percentage
1997 19 1213 1.57
1998 41 1194 3.43
1999 43 1151 3.74
2000 38 1113 3.41
2001 43 1070 4.02
2002 45 1025 4.39
2003 35 990 3.54
2004 38 952 3.99
2005 42 910 4.62
2006 37 873 4.24
2007 35 838 4.18
2008 21 817 2.57
2009 38 779 4.88
2010 21 758 2.77
2011 21 737 2.85
2012 23 714 3.22
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Likewise, the mortality ratio tended to decrease over 
time. This is underscored by the fact that the mortality 
ratio in the last 3 years of the study period was lower than 
in the preceding years and comparable to that of the gen-
eral population. This trend towards a decrease in mortality 
might reflect the introduction of more intensive treatment 
in the last two decades. Other explanations for the decreas-
ing mortality in this study might be that this cohort that was 
studied was a fixed cohort, hence new patients could not 
enter the study. As a result, the improved mortality could 
be a survival effect, in which patients with more “severe” 
RA died at the start of the study period (for example 
patients with shorter disease duration or with rheumatoid 
factor positive) and less “severe” patients survived and 
were followed up to the end of the study, which resulted 
in lower SMR at the end of the study period. We were able 
to study the association between disease duration and mor-
tality (adjusted for age and gender) in a sub-cohort of 882 
patients. There was no association between disease dura-
tion and mortality, which makes it more plausible that 
adjusting for disease duration would not have changed our 
results (data not shown).
Cause-specific mortality was determined through the 
primary cause of death. The primary cause of death is 
defined as the underlying cause of death, which started a 
sequence that finally resulted in death. This study showed 
that musculoskeletal and connective tissue diseases were 
the primary cause of a high number of deaths. Our results 
differ from other studies, which reported that RA is the 
primary cause of death in only a few cases [38]. This 













Fig. 1  Annual standardized mortality ratio and 95% confidence interval
Table 2  All-cause mortality in 
RA population
SMR standardized mortality ratio, adjusted for age and gender
Confidence interval Confidence interval Total Confidence interval
Men Lower Upper Women Lower Upper Lower Upper
(a) SMR (mean 3 years)
 1997–2000 1.42 0.72 2.50 1.63 1.07 2.37 1.54 1.08 2.14
 2001–2003 1.29 0.64 2.31 1.80 1.21 2.57 1.65 1.19 2.24
 2004–2006 1.57 0.82 2.71 1.75 1.14 2.57 1.68 1.20 2.30
 2007–2009 1.45 0.69 2.70 2.07 1.36 3.01 1.58 1.07 2.24
 2010–2012 0.76 0.25 1.82 1.56 0.96 2.42 1.14 0.71 1.73
(b) SMR (mean 5 years)
 1997–2002 1.49 0.78 2.58 1.66 1.07 2.44 1.63 1.15 2.22
 2003–2007 1.36 0.67 2.46 1.75 1.15 2.55 1.63 1.15 2.24
 2008–2012 1.02 0.39 2.17 1.42 0.85 2.24 1.29 0.83 1.91
(c) SMR (mean 15 years)
 1997–2012 1.32 1.13 1.55 1.62 1.46 1.80 1.54 1.41 1.67
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might be due to the definition of primary cause of death 
used by Statistics Netherlands. In their databank, the pri-
mary cause of death is defined as the underlying cause of 
death or the disease that started a sequence of incidents 
that resulted in death [39]. The primary cause of death in 
the category musculoskeletal and connective tissue dis-
eases was mostly RA and other types of arthritis. The sec-
ondary cause of death in patients who were classified as 
having a musculoskeletal and connective tissue disease as 
primary cause of death was injury, poisoning, and certain 
other consequences of external causes in 20%, circulatory 
diseases in 16%, respiratory diseases in 16%, and infec-
tions in 12% of the cases (data not shown). Different defi-
nitions of cause of death, used in national registries, will 
have important implications for study results. Therefore, 
results addressing cause-specific mortality, originating 
from different national registries, should be interpreted 
with caution.
Causes of death that were higher compared with the 
general population were diseases of the circulatory, respira-
tory, musculoskeletal, and digestive system. The change in 
health care could have resulted in different causes of death.
It is expected that current tight disease control translates 
into a lower CV mortality. Results of this study showed 
that the majority of the patients died due to CV diseases, 
which appeared to be the primary cause of death in 32% 
of the cases. This is somewhat lower than reported in older 
studies (conducted before implementation of intensive 
treatment and tight control of disease) where 40% of the 
patients with RA died due to CV diseases [34]. Our lower 
CV death rate might be related to currently applied medica-
tions. Nevertheless, it is still significantly higher than in the 
general population.
Mortality due to respiratory disease was also higher 
in the RA cohort compared with the general population. 
Although we did not look in detail to which specific respir-
atory diseases were registered in our cohort, other literature 
suggests that in most cases this will be respiratory infection 
[5]. The use of biologicals is associated with more severe 
infections [35–37], and therefore, it is expected that mortal-
ity due to respiratory disease would be higher than in the 
general population.
In our study, infection as a cause of death was not higher 
than that of the general population, while other studies 
report a higher incidence [34]. Infection was, however, 
often the secondary cause of death when RA was the pri-
mary cause of death. Adding the number of patients with 
infection as a secondary cause of death to the number of 
patients with infection as a primary cause of death resulted 
in a significantly higher cause-specific mortality ratio for 
infection (data not shown).
This is the first Dutch study reporting SMRs until 2012 
and the first Dutch study reporting the number of life-years 
lost in a well-defined cohort of patients with established 
RA. Moreover, the high number of deaths made it possi-
ble to study the cause-specific SMRs for a wide range of 
causes of death. Another strength of this study was that 
99% of the patients could be linked to the Municipal 
Register of the Statistics Netherlands. Furthermore, this 
study was conducted in a period in which the treatment of 
patients with RA changed (focus on tight disease control 
with the use of high-dose DMARDS from the 1990s and 
biologicals from 2000), which made it possible to investi-
gate the effect of the new medication. However, a limita-
tion of the study was that no comparisons could be made 
between the mortality in the study population and the 
Table 3  Cause-specific mortality in RA population (N = 535) over 15 years (1997–2012)
SMR standardized mortality ratio, adjusted for age and gender
Observed Expected SMR Confidence 
interval
Lower Upper
Circulatory system diseases 172 140 1.23 1.05 1.43
Neoplasms 112 108 1.03 0.85 1.24
Respiratory system diseases 62 44 1.42 1.09 1.82
Musculoskeletal and connective tissue diseases 49 3 17.4 12.85 22.97
Digestive system diseases 29 16 1.79 1.20 2.57
Mental and behavioural disorders 23 22 1.04 0.66 1.57
Abnormal clinical and laboratory signs not elsewhere classified 20 18 1.09 0.66 1.68
External causes of morbidity and mortality 17 11 1.55 0.90 2.48
Endocrine, nutritial, and metabolic diseases 14 14 1.01 0.55 1.69
Infections 10 5 1.90 0.91 3.50
Nervous system diseases 10 12 0.86 0.41 1.57
Genitourinary system, skin, subcutaneous tissue, blood, and blood-forming organs diseases 17 13 1.29 0.75 2.06
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general population corrected for confounders, such as use 
of medication, smoking, autoantibody profile, and struc-
tural damage, because data addressing all these confound-
ers were not available.
In this study, the mortality rate was calculated using 
indirect standardization. An advantage of indirect stand-
ardization is that only information about the total number 
of deaths for each year in the study population is needed. 
Thus, the standardized mortality rate can be calculated 
even if age-specific death rates of the study population at 
issue are not available or if the number of deaths for each 
age group is small [40]. A disadvantage is that it represents 
mortality for an age and gender distribution similar to the 
study population at issue. By comparing SMRs between 
studies, it is important to keep in mind that differences in 
SMRs can be caused by differences in age or gender distri-
bution between study populations at issue.
Comparing the mortality in our RA cohort with the mor-
tality in the general Dutch population may result in selec-
tion bias if the RA cohort does not represent the national 
patient population because of regional differences. How-
ever, all patients in this study were recruited from outpa-
tient clinics which have patients referred both from Amster-
dam and the northwest part of the Netherlands. Although 
the mortality in Amsterdam is higher than the mortality 
in the general Dutch population, the mortality in Amster-
dam combined with the northwest part of the Netherlands 
is comparable to the general Dutch population [41]. For 
future research, however, we recommend to study the mor-
tality in a RA cohort origination from a national registry.
Clinical relevance
In patients with established RA, the mortality risk is still 
higher than the mortality in the general Dutch population, 
with more than a life-year lost over a period of 15 years. 
As the primary cause of death is mostly cardiovascular dis-
ease, screening for and providing information about cardi-
ovascular diseases (and cardiovascular risk factors) in the 
rheumatology practice are important. On the other hand, 
the decrease in mortality coincided with changes in medi-
cation policy. Hence, tight disease control is also important 
to lower the high mortality risk in RA.
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